A Study Of (RTMS) And Intravenous (IV) Ketamine For Major Depressive Disorder

Overview

About this study

The goal of the study is to determine correlates of MMPI-3 and ANAM with response to rTMS and ketamine while investigating changes in optimism, resiliency, cognitive flexibility and coping abilities.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult patients ages 18 and older.
Received a clinical DSM-5-TR diagnosis of major depressive disorder (MDD)
Recommended to receive either rTMS or ketamine for treatment refractory MDD, failing to respond to at least two different antidepressants.
Adequate understanding of the English language.

Exclusion Criteria:

Current substance use disorder of any substance except nicotine and caffeine.
Current diagnosis of psychotic disorders.
Active borderline personality disorder which is the primary driving factor for their depression or would make them unstable to be safely treated with rTMS or IV ketamine.
Conditions or concomitant use of medications that are contraindications for treatment with either rTMS (e.g. ferromagnetic objects within 30 cm of the magnetic coil or seizure disorder) or IV ketamine (e.g. uncontrolled hypertension, use of stimulant medications).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/13/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Simon Kung, M.D.	Open for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Simon Kung, M.D.

Open for enrollment

More information

Publications

Publications are currently not available

Clinical Trials